Connect with us

Health & Fitness

Triplet Shows ‘Promising’ Activity in Unresectable/Metastatic CRC

Combining an EGFR inhibitor with a pair of checkpoint inhibitors can produce ‘promising’ activity in certain patients with colorectal cancer, according to an investigator from a phase 2 trial. Medscape Medical News

Published

on

Triplet Shows ‘Promising’ Activity in Unresectable/Metastatic CRC